

March 7, 2011

Press Release

[Mitsubishi Tanabe Pharma Corporation](#)

Transfer of Marketing Rights of 5 Long-term Listed Drugs to Tanabe Seiyaku Hanbai

Osaka, Japan, March 7, 2011---Mitsubishi Tanabe Pharma Corporation (President & CEO: Michihiro Tsuchiya) announced today that the Company will transfer the marketing rights of five long-term listed drugs to its consolidated subsidiary, Tanabe Seiyaku Hanbai Co., Ltd. (President: Masaki Yoshimoto), as of April 1, 2011.

The five drugs included in the transfer are: ALEGYSAL (for allergic disorders), AROFUTO (for myotonic diseases), INOLIN and BERACHIN (bronchodilators) and SESDEN (anticonvulsant). These drugs have long been widely used in medical practice.

Since October, 2009, the Company has started transferring its long-term listed drugs to Tanabe Seiyaku Hanbai. In October 2010, three long-listed drugs, including the ASPARA products and ASVERIN, were transferred to Tanabe Seiyaku Hanbai.

Tanabe Seiyaku Hanbai will strive to contribute to patients' health through a stable supply of generic drugs and other affordable drugs.

< 5 products in 13 items >

Product name	Ingredient	Efficacy
ALEGYSAL Tablets 5mg	Pemirolast potassium	Treatment of allergic disorders
ALEGYSAL Tablets 10mg		
ALEGYSAL Dry Syrup 0.5%		
AROFUTO Tablets 20mg	Afloqualone	Treatment of myotonic diseases
INOLIN Tablets 3mg	Trimetoquinol hydrochloride hydrate	Bronchodilator
INOLIN Powder 1%		
INOLIN Syrup 0.1%		
INOLIN 0.5% for inhalation		
BERACHIN Tablets 1mg	Tulobuterol hydrochloride	Bronchodilator
BERACHIN Dry Syrup for Children 0.1%		
SESDEN Capsules 30mg	Timepidium bromide hydrate	Anticonvulsant
SESDEN Fine Granules 6%		
SESDEN Injection 7.5mg		

<Contact for Inquiries>
Corporate Communications Department
Phone: +81 6-6205-5211